Labcorp launched COVID-19 test kits for small businesses to support return to work safely
On Apr. 20, 2021, LabCorp announced the availability of the Pixel by Labcorpﾮ COVID-19 PCR Test Home Collection…
Roswell Park, Wilmot Cancer Institute collaborated on first large study of immunotherapy in black cancer patients
On Apr. 20, 2021, a new collaboration between Roswell Park and the Wilmot Cancer Institute was announced that…
Pfizer and BioNTech to supply the European Union with 100 million additional doses of COMIRNATY
On Apr. 19, 2021, Pfizer and BioNTech announced supplying an additional 100 million doses of COMIRNATY, the companies…
Apabetaloneﾒs positive impact on COVID-19 in human lung cells published in biomedicines published
On Apr. 19, 2021, Resverlogix announced the publishing of an article titled: ﾓBromodomain and extraterminal protein inhibitor, apabetalone…
CureVac Swiss initiated rolling submission process for mRNA-based COVID-19 vaccine candidate with Swissmedic
On Apr. 19, 2021, CureVac and Celonic Group announced their partnership for the production of CureVacﾒs mRNA-based COVID-19…
Abbott began shipping BinaxNOWﾙ COVID-19 Ag self test to retailers
On Apr. 19, 2021, Abbott announced it had begun shipping its BinaxNOWﾙ COVID-19 Ag Self Test to retailers…
Human challenge trial launched to study immune response to COVID-19
On Apr. 19, 2021, researchers at the University of Oxford launched a human challenge trial to look at…
Broad Institute expanded COVID-19 viral sequencing efforts for variant surveillance in the Northeast
On Apr. 19, 2021, the Broad Institute of MIT in partnership with the Centers for Disease Control and…
Mayo Clinic study found colon cancer driven by hereditary gene mutations in 1 in 6 patients
On Apr. 19, 2021, the Mayo Clinic announced a study that bolstered evidence that colorectal cancer is often…
CytoDyn submitted Most Crucial Section of interim order to Health Canada for COVID-19 under rolling review
On Apr. 19, 2021, CytoDyn announced it had submitted the manufacturing section (CMC) of the application for an…
Biotechnology | COVID-19 | Diagnostics | Genomics | Infectious Disease | Non-Profit Research | Therapeutics
Texas A&M lab identified new COVID-19 variant; genome suggested potential resistance to antibodies
On Apr. 19, 2021, scientists at the Texas A&M University Global Health Research Complex (GHRC) announced they had…
Large clinical trial launched to study repurposed drugs to treat COVID-19 symptoms
On Apr. 19, 2021, the NIH announced that it was funding a large, randomized, placebo-controlled Phase 3 clinical…
Tonix Pharma entered worldwide licensing agreement to develop antiviral SARS-CoV-2 inhibitor for treatment of COVID-19
On Apr. 19, 2021, Tonix Pharmaceuticals and OyaGen announced an exclusive worldwide licensing agreement for an antiviral inhibitor…
FDA approved first immunotherapy for initial treatment of gastric cancer
On Apr. 16, 2021, the FDA approved Bristol-Myers Squibb’ s Opdivo (nivolumab), in combination with certain types of…
FDA revoked Emergency Use Authorization for monoclonal antibody bamlanivimab
On Apr. 16, 2021, the FDA revoked the emergency use authorization (EUA) that allowed for Eli Lilly’s investigational…
researchers discovered a gene that causes the most common form of muscular dystrophy in adults
On Apr. 15. 2021, a team of researchers led by the University of Minnesota Medical School announced they…
Merck announced phase 2/3 MOVe-IN study in hospitalized patients stopped
On Apr. 15, 2021, Merck and Ridgeback Biotherapeutics, and Ridgeback Biotherapeutics announced that based on a planned interim…
Merck discontinued development of MK-7110 for COVID-19
On Apr. 15, 2021, Merck announced the discontinuation of development of MK-7110 (formerly known as CD24Fc) for the…
Global shortage of innovative antibiotics fueled emergence and spread of drug-resistance
On Apr. 15, 2021, the World Health Organization (WHO) reported that the world was still failing to develop…
Risk of rare blood clotting higher for COVID-19 than for vaccines
On Apr. 15, 2021, researchers at the University of Oxford reported that the risk of the rare blood…
NIH funded new influenza research network
On Apr. 15, 2021, the National Institute of Allergy and Infectious Diseases (NIAID) announced it had had established…
Experimental antiviral for COVID-19 was effective in hamster study
On Apr. 15, 2021, the National Institutes of Health announced that the experimental antiviral drug MK-4482 significantly decreased…
IH closed enrollment in trial comparing COVID-19 treatment regimens
On Apr. 15, 2021, The National Institute of Allergy and Infectious Diseases (NIAID) announced that the fourth iteration…
INOVIO’s COVID-19 vaccine candidate provided broad cross-reactive immune responses In humans against variants
On Apr. 15, 2021, Inovio Pharmaceuticals announced the results of a study focusing on the human immune responses…
CytoDyn executed agreement with Chiral Pharma to provide up to 200,000 vials of leronlimab to Philippines
On Apr. 15, 2021, CytoDyn announced it had executed an exclusive supply and distribution agreement with Chiral Pharma…
AstraZeneca announced update on the safety of COVID-19 vaccine
On Apr. 14, 2021, following concern raised around thrombotic events, AstraZeneca offered its reassurance on the safety of…
Alternating vaccines trial expanded to include two additional vaccines
On Apr. 14, 2021, researchers running the Com-Cov study, launched in February to investigate alternating doses of the…
Moderna announced clinical progress from mRNA Vaccine
On Apr. 14, 2021, Moderna announced that results from a preclinical study of the Company’s COVID-19 variant-specific vaccine…
Novavax announced participation in University of Oxford Com-COV2 study comparing mixed COVID-19 vaccine combinations
On Apr. 14, 2021, Novavax announced its participation in an expanded investigator-initiated Phase 2 clinical trial called Comparing…
Mayo Clinic launched new technology platform ventures to revolutionize diagnostic medicine
On Apr. 14, 2021, the Mayo Clinic announced a new technology platform initiative to deliver the next generation…